Biologics are also commonly used to reduce inflammatory cytokines and include antitumor necrosis factor-alpha (TNF-α) antibodies which act through neutralizing TNF-α, an inflammatory cytokine responsible for much of the inflammatory damage seen in IBD. This evidence concerns the gene TNF and irritable bowel syndrome.